Navigation Links
Huifeng Bio-Pharmaceutical (HFGB) Provides Update on COS Application Status
Date:7/29/2008

COS Consultants Evaluate Purification Testing, Standards and Procedures

SHAANXI, China, July 29 /Xinhua-PRNewswire-FirstCall/ -- Huifeng Bio- Pharmaceutical Technology, Inc. (OTC Bulletin Board: HFGB), a leading developer and producer of plant extracts and raw materials used in the production of pharmaceuticals, nutraceuticals and food production, today released an investor update on the status of its application for COS approval for the delivery of Diosmin to Safic-Alcan.

COS, or European Certification of Suitability, approval is required before Huifeng can begin shipments of Diosmin to the European Community. As previously announced, Huifeng estimates COS approval in September.

In order to assure compliance with the application process, Huifeng recently retained and was visited by a certified COS approval consulting firm. The consultants performed a thorough, on-site inspection of Huifeng's Diosmin production facilities, including an evaluation of the purification testing, procedures and standards. In addition, the consultants provided the company with guidance pertaining to the COS application filing process.

"Huifeng is taking all necessary steps to keep pace with the established timeline for the COS application filing and approval process," stated Jing'An Wang, CEO/President of Huifeng. "Our COS consultants have not only assisted us in this process, but gave us very high marks regarding our Diosmin preparation and compliance with the COS standards."

COS certification is the final stage of approval for Huifeng to begin shipments of Diosmin to French company Safic-Alcan under a supply agreement announced last November. The supply agreement between Huifeng and Safic-Alcan grants Safic-Alcan exclusive rights to market Diosmin in the European market. The agreement also sets forth minimum guaranteed quantities to be delivered over each of the five years of the contract. The minimum quantity of Diosmin to be delivered in year on
'/>"/>

SOURCE Huifeng Bio-Pharmaceutical Technology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Huifeng Bio-Pharmaceutical (HFGB) Announces 2007 Full Year Results
2. Huifeng Bio-Pharmaceutical (HFGB) to Release First Quarter 2008 Earnings Results on May 15, 2008
3. Huifeng Bio-Pharmaceutical (HFGB) Announces No Earthquake Related Damage to Facilities
4. Huifeng Bio-Pharmaceutical (HFGB) Provides Update on Current Business and COS Certification
5. Huifeng Bio-Pharmaceutical (HFGB) Information to Be Available Through Standard & Poors Market Access Program
6. Huifeng Bio-pharmaceutical Technology Inc. Announces Strategic Alliance with Premier Media Service Inc.
7. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
8. Skystar Bio-Pharmaceutical Raises 2007 Revenue Guidance to $15.8 Million
9. Leading Overseas Scientists Establish High-Tech Bio-Pharmaceutical Enterprise in Changzhou
10. Sentry Enhances Offerings with Temperature-Controlled Custom Bio-Pharmaceutical Finishing Services
11. CardioDynamics Provides 2007 Shareholder Meeting Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Faso (PRWEB) July 10, 2014 ... today have access to an additional family planning ... access to contraception at all levels of the ... lower-dose formulation of a widely used contraceptive—Pfizer’s Depo-Provera® ... , Burkina Faso is the first of four ...
(Date:7/10/2014)... 10, 2014 Deep Knowledge Ventures ... Forum on ‘Commercialising Longevity Research’ and welcomed a ... the London Bioscience Innovation Center for the event, ... Aging Analytics Ltd. The meeting highlighted the need ... research for age-related disease, as well as the ...
(Date:7/10/2014)... Terascala, the industry leader in HPC ... former vice president of product management for Flexera Software, ... marketing. Terascala’s software when combined with leading compute and ... performance and most reliable solutions for processing big data. ... expansion and broaden its product portfolio. His leadership in ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, Inc., ... the relaunch of his highly informative blog, now named Stem ... What are Stem Cells ?” Dr. Harman’s purpose for ... the basics of stem cell therapy so that pet owners ... treatment when considering regenerative medicine. , A veterinarian by trade, ...
Breaking Biology Technology:Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... A report on the California biomedical industry published ... success stories from Larta Institute, a consulting firm that ... to market. According to CHI,s 2011 ... growing force in the past few years in the ...
... BOSTON, Feb. 11, 2011 Tufts University today announced ... Partnerships Web site/HUB:   www.tuftspharmapartners.org .   ... designed to create and manage a diverse portfolio of ... Institute was developed and is managed by Tufts University ...
... LOS ANGELES, Feb. 11, 2011 Genesis Biopharma, ... a biotechnology company developing targeted cancer therapies, today announced ... Chief Executive Officer.  Mr. Cataldo succeeds Robert Brooke, who ...  In addition, the Company named Michael Handelman as Chief ...
Cached Biology Technology:Larta Institute NIH Success Stories Featured in 2011 California Biomedical Industry Report 2Tufts Launches Institute for Biopharmaceutical Partnerships 2Tufts Launches Institute for Biopharmaceutical Partnerships 3Tufts Launches Institute for Biopharmaceutical Partnerships 4Genesis Biopharma Announces Management and Board Changes 2Genesis Biopharma Announces Management and Board Changes 3
(Date:7/11/2014)... Conservation Society shows that no-take zones in Belize ... as lobster, conch, and fish recover from overfishing, ... , The reporttitled "Review of the Benefits of ... from no-take areas around the world. The report ... expert in marine protected areas and fisheries management. ...
(Date:7/11/2014)... The Mills Canyon fire started near the City of ... of local resources, the fire quickly grew to over ... cause of the fire is under investigation by the ... is working with existing local resources in developing fire ... Forest Service (USFS), Washington State Department of Natural Resources, ...
(Date:7/11/2014)... available in German . ... that uses the refraction of X-rays through a specimen ... with this method are often of much higher quality ... team of Prof. Franz Pfeiffer are particularly interested in ... including X-ray phase-contrast imaging. One main goal is ...
Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2New simple setup for X-ray phase contrast 2
... that tamps down stem cell activity ironically, perhaps, encourages ... researchers report. Understanding how these new brain cells "decide" ... is of special interest because changes in their activity ... illness and aging. "We,ve identified a critical ...
... United States has resulted in the discovery of a ... diseases particularly eosinophil-associated disorders. The researchers from ... have discovered how this pathway kills eosinophils before they ... the blood, but when the body produces too many ...
... researchers have found that zinc can ,starve, one of ... of an essential metal. The finding, by infectious ... University of Queensland, opens the way for further work ... Streptococcus pneumoniae . Streptococcus pneumoniae is ...
Cached Biology News:SIGNAL found to enhance survival of new brain cells 2Discovery may lead to new treatments for allergic diseases 2How zinc starves lethal bacteria to stop infection 2
...
Mouse monoclonal [H4B4] to LAMP2 - Lysosome Marker (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 3920 SwissProtID: P13473...
Mouse monoclonal [IA-C6] to MHC Class II I Ab + Ad (FITC) ( Abpromise for all tested applications). Antigen: Tissue / cell preparation of Purified Mouse lymph node B cells...
...
Biology Products: